JP2022543960A - Mhc ii/cii複合体の生成 - Google Patents
Mhc ii/cii複合体の生成 Download PDFInfo
- Publication number
- JP2022543960A JP2022543960A JP2021572488A JP2021572488A JP2022543960A JP 2022543960 A JP2022543960 A JP 2022543960A JP 2021572488 A JP2021572488 A JP 2021572488A JP 2021572488 A JP2021572488 A JP 2021572488A JP 2022543960 A JP2022543960 A JP 2022543960A
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- cii
- mhc
- drb1
- chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 607
- 210000004027 cell Anatomy 0.000 claims abstract description 160
- 238000000034 method Methods 0.000 claims abstract description 98
- 210000004962 mammalian cell Anatomy 0.000 claims abstract description 48
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 48
- 101001100327 Homo sapiens RNA-binding protein 45 Proteins 0.000 claims description 152
- 102100038823 RNA-binding protein 45 Human genes 0.000 claims description 152
- 108091054438 MHC class II family Proteins 0.000 claims description 105
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 claims description 104
- 102000043131 MHC class II family Human genes 0.000 claims description 102
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 101
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 86
- 239000000203 mixture Substances 0.000 claims description 81
- 102000040430 polynucleotide Human genes 0.000 claims description 68
- 108091033319 polynucleotide Proteins 0.000 claims description 68
- 239000002157 polynucleotide Substances 0.000 claims description 67
- RCPOVANIIKXVTB-YPPRVYOWSA-N Galactosylhydroxylysine Chemical group NCCCC[C@@H](C(O)=O)N(O)C1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O RCPOVANIIKXVTB-YPPRVYOWSA-N 0.000 claims description 62
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical group NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 claims description 54
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 claims description 48
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 claims description 48
- 150000001413 amino acids Chemical group 0.000 claims description 43
- 108010035532 Collagen Proteins 0.000 claims description 38
- 102000008186 Collagen Human genes 0.000 claims description 38
- 229920001436 collagen Polymers 0.000 claims description 38
- 230000000694 effects Effects 0.000 claims description 38
- 108010020504 2-Oxoglutarate 5-Dioxygenase Procollagen-Lysine Proteins 0.000 claims description 34
- 102000008490 2-Oxoglutarate 5-Dioxygenase Procollagen-Lysine Human genes 0.000 claims description 34
- 108700028369 Alleles Proteins 0.000 claims description 30
- 229920001184 polypeptide Polymers 0.000 claims description 30
- 102000004190 Enzymes Human genes 0.000 claims description 29
- 108090000790 Enzymes Proteins 0.000 claims description 29
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 28
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 28
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 27
- 239000004472 Lysine Substances 0.000 claims description 27
- 230000004481 post-translational protein modification Effects 0.000 claims description 25
- 238000005734 heterodimerization reaction Methods 0.000 claims description 24
- 108010058597 HLA-DR Antigens Proteins 0.000 claims description 19
- 102000006354 HLA-DR Antigens Human genes 0.000 claims description 19
- 108010080693 UDP glucose-collagen glucosyltransferase Proteins 0.000 claims description 18
- 108010069778 UDPgalactose-collagen galactosyltransferase Proteins 0.000 claims description 18
- 238000004519 manufacturing process Methods 0.000 claims description 18
- 230000000295 complement effect Effects 0.000 claims description 15
- 239000006228 supernatant Substances 0.000 claims description 15
- 101000903686 Homo sapiens Procollagen galactosyltransferase 1 Proteins 0.000 claims description 14
- 102100022982 Procollagen galactosyltransferase 1 Human genes 0.000 claims description 13
- 102100035199 Procollagen glycosyltransferase Human genes 0.000 claims description 12
- 101000903791 Homo sapiens Procollagen galactosyltransferase 2 Proteins 0.000 claims description 11
- 102100022973 Procollagen galactosyltransferase 2 Human genes 0.000 claims description 11
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 10
- 208000037976 chronic inflammation Diseases 0.000 claims description 10
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims description 10
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 10
- 230000004927 fusion Effects 0.000 claims description 9
- 230000002378 acidificating effect Effects 0.000 claims description 8
- 208000027625 autoimmune inner ear disease Diseases 0.000 claims description 8
- 210000003292 kidney cell Anatomy 0.000 claims description 7
- 238000012258 culturing Methods 0.000 claims description 6
- 201000008482 osteoarthritis Diseases 0.000 claims description 6
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 5
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 5
- 102000006833 Multifunctional Enzymes Human genes 0.000 claims description 5
- 108010047290 Multifunctional Enzymes Proteins 0.000 claims description 5
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 5
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 5
- 210000002950 fibroblast Anatomy 0.000 claims description 5
- 208000016604 Lyme disease Diseases 0.000 claims description 4
- 208000027530 Meniere disease Diseases 0.000 claims description 4
- 208000034967 Non-Radiographic Axial Spondyloarthritis Diseases 0.000 claims description 4
- 206010065159 Polychondritis Diseases 0.000 claims description 4
- 210000000963 osteoblast Anatomy 0.000 claims description 4
- 230000000306 recurrent effect Effects 0.000 claims description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 4
- 230000000640 hydroxylating effect Effects 0.000 claims description 3
- 108010091748 peptide A Proteins 0.000 claims 1
- 230000014509 gene expression Effects 0.000 abstract description 31
- 238000011065 in-situ storage Methods 0.000 abstract description 10
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract description 8
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract description 8
- VYLDPSVXLWTIAJ-HNNXBMFYSA-N n-[(1s)-2-methyl-1-(pyridin-4-ylcarbamoyl)propyl]cyclohexanecarboxamide Chemical compound N([C@@H](C(C)C)C(=O)NC=1C=CN=CC=1)C(=O)C1CCCCC1 VYLDPSVXLWTIAJ-HNNXBMFYSA-N 0.000 description 424
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 231
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 231
- ZJZBQHWSENWEMY-DZQJYWQESA-N galactose grease Chemical compound COC(=O)CCCCCCCCO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O ZJZBQHWSENWEMY-DZQJYWQESA-N 0.000 description 123
- 108090000623 proteins and genes Proteins 0.000 description 115
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 description 106
- 210000001744 T-lymphocyte Anatomy 0.000 description 85
- 102000004169 proteins and genes Human genes 0.000 description 66
- 235000018102 proteins Nutrition 0.000 description 59
- 230000027455 binding Effects 0.000 description 58
- 125000003275 alpha amino acid group Chemical group 0.000 description 50
- 235000001014 amino acid Nutrition 0.000 description 48
- 108010002350 Interleukin-2 Proteins 0.000 description 44
- 102000000588 Interleukin-2 Human genes 0.000 description 44
- 229940024606 amino acid Drugs 0.000 description 40
- 238000003776 cleavage reaction Methods 0.000 description 36
- 230000007017 scission Effects 0.000 description 36
- UTIRJVJBKWSIOX-ZTPIPZIISA-N 5-[(alpha-D-glucopyranosyl-(1->2)-beta-D-galactopyranosyl)oxy]-L-lysine Chemical group OC(=O)[C@@H](N)CCC(CN)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 UTIRJVJBKWSIOX-ZTPIPZIISA-N 0.000 description 35
- 239000007787 solid Substances 0.000 description 33
- 210000004408 hybridoma Anatomy 0.000 description 32
- 235000018977 lysine Nutrition 0.000 description 31
- 239000002773 nucleotide Substances 0.000 description 29
- 125000003729 nucleotide group Chemical group 0.000 description 28
- 229940088598 enzyme Drugs 0.000 description 27
- 241000699670 Mus sp. Species 0.000 description 26
- 206010003246 arthritis Diseases 0.000 description 26
- 239000000427 antigen Substances 0.000 description 25
- 108091007433 antigens Proteins 0.000 description 25
- 102000036639 antigens Human genes 0.000 description 25
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 24
- 101100450563 Mus musculus Serpind1 gene Proteins 0.000 description 24
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 23
- 108091008874 T cell receptors Proteins 0.000 description 21
- 229920001287 Chondroitin sulfate Polymers 0.000 description 20
- 238000001994 activation Methods 0.000 description 20
- 230000001225 therapeutic effect Effects 0.000 description 20
- 238000011282 treatment Methods 0.000 description 20
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 19
- 108020004414 DNA Proteins 0.000 description 19
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 19
- 230000004913 activation Effects 0.000 description 19
- 229940059329 chondroitin sulfate Drugs 0.000 description 19
- 238000012546 transfer Methods 0.000 description 19
- 108020004459 Small interfering RNA Proteins 0.000 description 18
- 108010090804 Streptavidin Proteins 0.000 description 18
- 230000000638 stimulation Effects 0.000 description 18
- 239000013598 vector Substances 0.000 description 18
- 108091027967 Small hairpin RNA Proteins 0.000 description 17
- 238000000338 in vitro Methods 0.000 description 17
- 239000000047 product Substances 0.000 description 17
- 229930182852 proteinogenic amino acid Natural products 0.000 description 17
- 230000004044 response Effects 0.000 description 17
- 229920002567 Chondroitin Polymers 0.000 description 16
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 16
- 229920002674 hyaluronan Polymers 0.000 description 16
- 230000004048 modification Effects 0.000 description 16
- 238000012986 modification Methods 0.000 description 16
- 108010002352 Interleukin-1 Proteins 0.000 description 15
- 102000000589 Interleukin-1 Human genes 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 15
- 208000009386 Experimental Arthritis Diseases 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 230000013595 glycosylation Effects 0.000 description 14
- 238000006206 glycosylation reaction Methods 0.000 description 14
- 239000004055 small Interfering RNA Substances 0.000 description 13
- 102000004127 Cytokines Human genes 0.000 description 12
- 108090000695 Cytokines Proteins 0.000 description 12
- 108090000190 Thrombin Proteins 0.000 description 12
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Natural products N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 12
- 229960004072 thrombin Drugs 0.000 description 12
- -1 Gal-HK264) Chemical compound 0.000 description 11
- 238000001514 detection method Methods 0.000 description 11
- 239000013604 expression vector Substances 0.000 description 11
- 230000001404 mediated effect Effects 0.000 description 11
- 108020004999 messenger RNA Proteins 0.000 description 11
- 229920002704 polyhistidine Polymers 0.000 description 11
- 108010029657 HLA-DRB1*04:01 antigen Proteins 0.000 description 10
- 108010076504 Protein Sorting Signals Proteins 0.000 description 10
- 230000006287 biotinylation Effects 0.000 description 10
- 238000007413 biotinylation Methods 0.000 description 10
- 229940099552 hyaluronan Drugs 0.000 description 10
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 210000005259 peripheral blood Anatomy 0.000 description 10
- 239000011886 peripheral blood Substances 0.000 description 10
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 9
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 9
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 9
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 9
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
- 230000002255 enzymatic effect Effects 0.000 description 9
- 238000003197 gene knockdown Methods 0.000 description 9
- 230000009368 gene silencing by RNA Effects 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 101150077518 PLOD3 gene Proteins 0.000 description 8
- 229960002685 biotin Drugs 0.000 description 8
- 235000020958 biotin Nutrition 0.000 description 8
- 239000011616 biotin Substances 0.000 description 8
- 210000002744 extracellular matrix Anatomy 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 230000014616 translation Effects 0.000 description 8
- 239000004471 Glycine Substances 0.000 description 7
- 101000595913 Homo sapiens Procollagen glycosyltransferase Proteins 0.000 description 7
- 230000006044 T cell activation Effects 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000000692 anti-sense effect Effects 0.000 description 7
- 150000002016 disaccharides Chemical class 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000000684 flow cytometry Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000003053 immunization Effects 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 238000004949 mass spectrometry Methods 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 230000003204 osmotic effect Effects 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 238000001542 size-exclusion chromatography Methods 0.000 description 7
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 6
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 6
- 102100032937 CD40 ligand Human genes 0.000 description 6
- 108010041390 Collagen Type II Proteins 0.000 description 6
- 102000000503 Collagen Type II Human genes 0.000 description 6
- 229920002971 Heparan sulfate Polymers 0.000 description 6
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 210000000845 cartilage Anatomy 0.000 description 6
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 239000000562 conjugate Substances 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 102000037865 fusion proteins Human genes 0.000 description 6
- 108020001507 fusion proteins Proteins 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 239000008241 heterogeneous mixture Substances 0.000 description 6
- 229960003160 hyaluronic acid Drugs 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 239000004033 plastic Substances 0.000 description 6
- 229920003023 plastic Polymers 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- 108010039343 HLA-DRB1 Chains Proteins 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 102000005396 glutamine synthetase Human genes 0.000 description 5
- 108020002326 glutamine synthetase Proteins 0.000 description 5
- 239000000833 heterodimer Substances 0.000 description 5
- 230000033444 hydroxylation Effects 0.000 description 5
- 238000005805 hydroxylation reaction Methods 0.000 description 5
- 230000010354 integration Effects 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 210000003289 regulatory T cell Anatomy 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- 241000701022 Cytomegalovirus Species 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 4
- 102000003960 Ligases Human genes 0.000 description 4
- 108090000364 Ligases Proteins 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000003435 antirheumatic agent Substances 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 150000001720 carbohydrates Chemical group 0.000 description 4
- 230000005859 cell recognition Effects 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 239000002988 disease modifying antirheumatic drug Substances 0.000 description 4
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 230000002519 immonomodulatory effect Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 108010028930 invariant chain Proteins 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 108091070501 miRNA Proteins 0.000 description 4
- 239000002679 microRNA Substances 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 210000004976 peripheral blood cell Anatomy 0.000 description 4
- 230000001323 posttranslational effect Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 230000003827 upregulation Effects 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- 238000010442 DNA editing Methods 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 206010014025 Ear swelling Diseases 0.000 description 3
- 108060003306 Galactosyltransferase Proteins 0.000 description 3
- 102000030902 Galactosyltransferase Human genes 0.000 description 3
- 108010067802 HLA-DR alpha-Chains Proteins 0.000 description 3
- 108010053491 HLA-DR beta-Chains Proteins 0.000 description 3
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 208000012659 Joint disease Diseases 0.000 description 3
- 102000057297 Pepsin A Human genes 0.000 description 3
- 108090000284 Pepsin A Proteins 0.000 description 3
- 230000005867 T cell response Effects 0.000 description 3
- 108010022394 Threonine synthase Proteins 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 235000009697 arginine Nutrition 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- DGQLVPJVXFOQEV-NGOCYOHBSA-N carminic acid Chemical compound OC1=C2C(=O)C=3C(C)=C(C(O)=O)C(O)=CC=3C(=O)C2=C(O)C(O)=C1[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O DGQLVPJVXFOQEV-NGOCYOHBSA-N 0.000 description 3
- 229940114118 carminic acid Drugs 0.000 description 3
- 235000012730 carminic acid Nutrition 0.000 description 3
- 239000004106 carminic acid Substances 0.000 description 3
- 230000003915 cell function Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 102000004419 dihydrofolate reductase Human genes 0.000 description 3
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000002452 interceptive effect Effects 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 108091005601 modified peptides Proteins 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 229940111202 pepsin Drugs 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000008488 polyadenylation Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 2
- 108091033409 CRISPR Proteins 0.000 description 2
- 238000010354 CRISPR gene editing Methods 0.000 description 2
- 208000005243 Chondrosarcoma Diseases 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 108050001049 Extracellular proteins Proteins 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101500028562 Homo sapiens Class-II-associated invariant chain peptide Proteins 0.000 description 2
- 101500024089 Homo sapiens Corticotropin-like intermediary peptide Proteins 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 230000004989 O-glycosylation Effects 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 2
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 241000219061 Rheum Species 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 239000012505 Superdex™ Substances 0.000 description 2
- 238000010459 TALEN Methods 0.000 description 2
- 108091036066 Three prime untranslated region Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 230000002456 anti-arthritic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000009881 electrostatic interaction Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 235000004554 glutamine Nutrition 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000002516 postimmunization Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 230000006337 proteolytic cleavage Effects 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000009258 tissue cross reactivity Effects 0.000 description 2
- 230000003614 tolerogenic effect Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000003146 transient transfection Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 101150090724 3 gene Proteins 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- XAJRHVUUVUPFQL-ACZMJKKPSA-N Asp-Glu-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O XAJRHVUUVUPFQL-ACZMJKKPSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 108050003866 Bifunctional ligase/repressor BirA Proteins 0.000 description 1
- 102100033743 Biotin-[acetyl-CoA-carboxylase] ligase Human genes 0.000 description 1
- 108700031361 Brachyury Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 101150112757 CAS gene Proteins 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 101710096438 DNA-binding protein Proteins 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 108020005004 Guide RNA Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102100031547 HLA class II histocompatibility antigen, DO alpha chain Human genes 0.000 description 1
- 102100029966 HLA class II histocompatibility antigen, DP alpha 1 chain Human genes 0.000 description 1
- 108010010378 HLA-DP Antigens Proteins 0.000 description 1
- 102000015789 HLA-DP Antigens Human genes 0.000 description 1
- 108010062347 HLA-DQ Antigens Proteins 0.000 description 1
- 108010046732 HLA-DR4 Antigen Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000866278 Homo sapiens HLA class II histocompatibility antigen, DO alpha chain Proteins 0.000 description 1
- 101000864089 Homo sapiens HLA class II histocompatibility antigen, DP alpha 1 chain Proteins 0.000 description 1
- 101000930802 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 1 chain Proteins 0.000 description 1
- 101000968032 Homo sapiens HLA class II histocompatibility antigen, DR beta 3 chain Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101000972485 Homo sapiens Lupus La protein Proteins 0.000 description 1
- 101000595904 Homo sapiens Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 Proteins 0.000 description 1
- 101000595907 Homo sapiens Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 1
- 206010023215 Joint effusion Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101001082628 Mus musculus H-2 class II histocompatibility antigen gamma chain Proteins 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108091093105 Nuclear DNA Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 102100035198 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 Human genes 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102100037116 Transcription elongation factor 1 homolog Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229960003697 abatacept Drugs 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 230000000599 auto-anti-genic effect Effects 0.000 description 1
- 230000008267 autocrine signaling Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000000981 bystander Effects 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 108091006007 citrullinated proteins Proteins 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000006690 co-activation Effects 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000012084 conversion product Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- KVEAILYLMGOETO-UHFFFAOYSA-H dicalcium magnesium diphosphate Chemical compound P(=O)([O-])([O-])[O-].[Mg+2].[Ca+2].[Ca+2].P(=O)([O-])([O-])[O-] KVEAILYLMGOETO-UHFFFAOYSA-H 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000013931 endocrine signaling Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000009760 functional impairment Effects 0.000 description 1
- 125000002519 galactosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 102000052972 human La Human genes 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000035990 intercellular signaling Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000007108 local immune response Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000001293 nucleolytic effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000014306 paracrine signaling Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- LQRJAEQXMSMEDP-XCHBZYMASA-N peptide a Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)NCCCC[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C/C=1C=CC=CC=1)C(N)=O)C(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C\C1=CC=CC=C1 LQRJAEQXMSMEDP-XCHBZYMASA-N 0.000 description 1
- 102000023856 peptide binding proteins Human genes 0.000 description 1
- 108091008399 peptide binding proteins Proteins 0.000 description 1
- 239000000863 peptide conjugate Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 208000030683 polygenic disease Diseases 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000001711 protein immunostaining Methods 0.000 description 1
- 230000020978 protein processing Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 239000002684 recombinant hormone Substances 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000010282 redox signaling Effects 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 1
- 235000016491 selenocysteine Nutrition 0.000 description 1
- 229940055619 selenocysteine Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 102000023888 sequence-specific DNA binding proteins Human genes 0.000 description 1
- 108091008420 sequence-specific DNA binding proteins Proteins 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 239000002924 silencing RNA Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 230000005477 standard model Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 231100000617 superantigen Toxicity 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- JGVWCANSWKRBCS-UHFFFAOYSA-N tetramethylrhodamine thiocyanate Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(SC#N)C=C1C(O)=O JGVWCANSWKRBCS-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000002477 vacuolizing effect Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0684—Cells of the urinary tract or kidneys
- C12N5/0687—Renal stem cells; Renal progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/605—MHC molecules or ligands thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
- C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/00041—Use of virus, viral particle or viral elements as a vector
- C12N2740/00043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
哺乳動物細胞内に組換えMHC II/CIIペプチド複合体を生成する方法
1)DR4構築物:
・DR4構築物α鎖(配列番号16)、DRA*0101細胞外α鎖領域に先行するシグナルペプチド(実線下線付き)、TEV切断部位(太字)、cFosドメイン(太字および実線下線付き)、およびビオチン化部位(BirA、斜体および実線下線付き)を含む配列:
・上述のDR4構築物α鎖(配列番号16)
・hCLIPmutを有するDR4構築物β鎖(配列番号20)、Strepタグの直前に先行するシグナルペプチド(太字および二重実線下線付き)および変異hCLIPペプチド(斜体および実線下線付き)、各部位のグリシンリンカーで囲まれたトロンビン切断部位(太字および点線下線付き)、DRB*0401細胞外領域(実線下線付き)、TEV切断部位(太字)、cJunドメイン(太字および実線下線付き)、およびHisタグ(斜体)を含む配列:
・Aq構築物α鎖(配列番号21)、Aq細胞外α鎖領域に先行するシグナルペプチド(実線下線付き)、TEV切断部位(太字)、cFosドメイン(太字および実線下線付き)およびビオチン化部位(BirA、斜体および実線下線付き)を含む配列:
・上述のAq構築物α鎖(配列番号21)
・mCLIPペプチドを有するAq構築物β鎖(配列番号24)、Strepタグの直前に先行するシグナルペプチド(太字および二重実線下線付き)およびマウスCLIPmtペプチド(斜体および実線下線付き)、各部位のグリシンリンカーによって囲まれたトロンビン切断部位(太字および点線下線付き)、Aq細胞外領域(実線下線付き)、TEV切断部位(太字)、cJunドメイン(太字および実線下線付き)、およびHisタグ(斜体)を含む配列:
・cFosドメイン(配列番号26):LTDTLQAETDQLEDEKSALQTEIANLLKEKEKLEFILAAH
・cJunドメイン(配列番号27):RIARLEEKVKTLKAQNSELASTANMLREQVAQLKQKVMNH
・修飾ヒトCLIPペプチド(配列番号28):PVSKARMATGALAQA
・ラットCIIペプチド259~273(配列番号29):GIAGFKGEQGPKGET
・ストレプトアビジンタグ(配列番号30):SAWSHPQFEK
組換えMHC II/CIIペプチド複合体を含む組成物
治療での使用
組換えMHC II/CIIペプチド複合体を含む四量体
上記を考慮して、本発明はさらに以下の項目を包含することが分かる。
項目1
組換えMHC II/CIIペプチド複合体を含む組成物であって、この組成物は、
(a)少なくともα1ドメインを含むMHCクラスIIα鎖の細胞外領域、
(b)少なくともβ1ドメインを含むMHCクラスIIβ鎖の細胞外領域、および
(c)リンカーペプチドによってMHCクラスIIα鎖またはMHCクラスIIβ鎖、好ましくはMHCクラスIIβ鎖のN末端に融合されたコラーゲンIIペプチド(CIIペプチド)を含み、
CIIペプチドは、AGFKGEQGPKG、AGFKGEQGPXG、AGFKGEXGPKG、AGFKGXQGPKG、AGFKXEQGPKG、AGFKGEXGPXG、AGFKGXQGPXG、およびAGFKXEQGPXGからなる群から選択されるアミノ酸配列を含み、
MHC II/CIIペプチド複合体は、翻訳後修飾CIIペプチドを含み、好ましくは、CIIペプチドの第1のリジン残基は、ヒドロキシリジン(Hyl)であるか、またはO-グリコシル化Hylである。
項目2
項目1に記載の組成物であって、
(a)MHCクラスIIα鎖の細胞外領域は、α1ドメインおよびα2ドメインを含む、かつ/あるいは、
(b)MHCクラスIIβ鎖の細胞外領域は、β1ドメインおよびβ2ドメインを含む。
項目3
項目1または2に記載の組成物であって、第1のリジン残基は、ガラクトシルヒドロキシリジンである。
項目4
項目1~3のいずれか1項目に記載の組成物であって、CIIペプチドは、リンカーペプチドによってβ1ドメインのN末端に融合されている。
項目5
項目1~4のいずれか1項目に記載の組成物であって、少なくともα1ドメインはDRA*0101に由来し、少なくともβ1ドメインは、DRB1*0401、DRB1*0404、DRB1*0405、DRB1*0408、DRB1*0409、DRB1*0101、DRB1*0102、DRB1*1001、DRB1*1402、およびDRB1*1303からなる群から選択されるHLA-DR対立遺伝子に由来し、好ましくはDRB1*0401に由来する。
項目6
項目1~5のいずれか1項目に記載の組成物であって、CIIペプチドは、AGFKGEQGPKG、好ましくはAGFKGEQGPKGEP、より好ましくはGIAGFKGEQGPKGEPのアミノ酸配列を含む。
項目7
項目1~6のいずれか1項目に記載の組成物であって、CIIペプチドは、第1のリジン残基のみを含み、さらなるK(any further K)は変異していて、好ましくはR、A、GまたはQ、より好ましくはRに変異している。
項目8
項目1~7のいずれか1項目に記載の組成物であって、
(a)少なくともα1ドメインを含むMHCクラスIIα鎖の細胞外領域、
(b)少なくともβ1ドメインを含むMHCクラスIIβ鎖の細胞外領域、および
(c)リンカーペプチドによってMHCクラスIIα鎖またはMHCクラスIIβ鎖のN末端に融合したコラーゲンIIペプチド(CIIペプチド)は、単一の融合ポリペプチドとして発現される。
項目9
項目1~7のいずれか1項目に記載の組成物であって、この組成物は、
(a)少なくともα1ドメインを含むMHCクラスIIα鎖の細胞外領域を含む第1のポリペプチド、
(b)少なくともβ1ドメインを含むMHCクラスIIβ鎖の細胞外領域を含む第2のポリペプチド、および
(c)リンカーペプチドによってMHCクラスIIα鎖またはMHCクラスIIβ鎖のN末端に融合したコラーゲンIIペプチド(CIIペプチド)を含む。
項目10
項目9に記載の組成物であって、MHCクラスIIα鎖は、そのC末端でロイシンジッパーヘテロ二量体化モチーフの第1の機能的ドメインに融合され、かつMHCクラスIIβ鎖は、そのC末端でロイシンジッパーヘテロ二量体化モチーフの第2の相補的機能的ドメインに融合されている。
項目11
項目10に記載の組成物であって、第1の機能ドメインおよび第2の相補的機能ドメインは、
(a)酸性および塩基性のロイシンジッパーヘテロ二量体化ドメイン、および/または
(b)jun-fosロイシンジッパーモチーフである。
項目12
項目1~11のいずれか1項目に記載の組成物はさらに、CIIペプチドを含むMHC II/CIIペプチド複合体を含み、CIIペプチドの第1のリジン残基は未修飾である。
項目13
翻訳後修飾(例えばO-グリコシル化)CIIペプチドを含むMHC II/CIIペプチド複合体を生成する方法であって、この方法は、
(a)哺乳動物細胞を
(i)少なくともα1ドメインを含むMHC IIα鎖の細胞外領域をコードするポリヌクレオチド、
(ii)少なくともβ1ドメインを含むMHC IIβ鎖の細胞外領域をコードするポリヌクレオチド、および
(iii)リンカーペプチドによってMHCクラスIIα鎖またはMHCクラスIIβ鎖、好ましくはMHCクラスIIβ鎖のN末端に融合されたコラーゲンIIペプチド(CIIペプチド)をコードするポリヌクレオチドであって、ここでCIIペプチドは、AGFKGEQGPKG、AGFKGEQGPXG、AGFKGEXGPKG、AGFKGXQGPKG、AGFKXEQGPKG、AGFKGEXGPXG、AGFKGXQGPXG、およびAGFKXEQGPXGからなる群から選択されるアミノ酸配列を含む、ポリヌクレオチド
で遺伝子導入する工程、
(b)MHC II/CIIペプチド複合体の生成に適する条件で哺乳動物細胞を培養する工程、および
(c)翻訳後修飾CIIペプチドを含むMHC II/CIIペプチド複合体を含む細胞上清および場合によっては細胞を回収する工程を含み、好ましくはここでCIIペプチドの第1のリジン残基は、ヒドロキシリジン(Hyl)であり、またはO-グリコシル化Hylである。
項目14
項目13に記載の方法はさらに、MHC II/CIIペプチド複合体のCIIペプチドの翻訳後修飾、好ましくはグリコシル化特性を分析する工程を含む。
項目15
項目13または14に記載の方法であって、第1のリジン残基は、ガラクトシルヒドロキシリジンである。
項目16
項目13~15のいずれか1項目に記載の方法であって、哺乳動物細胞は、
(a)リジンをヒドロキシリジン(Hyl)にヒドロキシル化すること、かつHylをガラクトシルヒドロキシリジン(Gal-Hyl)にガラクトシル化することを含む、コラーゲン中のリジン残基を翻訳後修飾する酵素を含む、かつ/あるいは
(b)リジン水酸化酵素およびコラーゲンガラクトース転移酵素、好ましくはリジン水酸化酵素1(LH1)および/またはリジン水酸化酵素2(LH2)およびコラーゲンガラクトース転移酵素GLT25D1および/またはGLT25D2、好ましくはGLT25D1を含む。
項目17
項目16に記載の方法であって、細胞は、
(a)腎細胞、線維芽細胞、または骨芽細胞、好ましくは腎細胞、より好ましくはHEK 293細胞株である、あるいは
(b)リジン水酸化酵素およびコラーゲンガラクトース転移酵素、好ましくはリジン水酸化酵素1(LH1)および/またはリジン水酸化酵素2(LH2)およびコラーゲンガラクトース転移酵素GLT25D1および/またはGLT25D2を組換え発現する遺伝子操作細胞である。
項目18
項目13~17のいずれか1項目に記載の方法であって、哺乳動物細胞は、
(a)ガラクトシルヒドロキシリシルグルコース転移酵素活性を欠いている、
(b)多機能酵素であるLH3を欠いている、あるいは
(c)ガラクトシルヒドロキシリシルグルコース転移酵素活性を欠く変異性LH3酵素を含む。
項目19
項目18に記載の方法であって、哺乳動物細胞は、ガラクトシルヒドロキシリシルグルコース転移酵素活性が低下するか、またはその活性が無いように遺伝子操作され、好ましくは
(a)LH3をコードするPLOD3遺伝子は、変異しているか、または排除されている、
(b)LH3酵素は、ガラクトシルヒドロシリシルグルコース転移酵素活性を欠く変異性LH3酵素である、あるいは
(c)LH3の発現は、RNA干渉によって阻害される。
項目20
項目13~16のいずれか1項目に記載の方法はさらに、工程(b)に従って哺乳動物細胞を培養する間にカルミン酸を添加することを含む。
項目21
項目13~20のいずれか1項目に記載の方法であって、
(a)MHCクラスIIα鎖の細胞外領域は、α1ドメインおよびα2ドメインを含む、かつ/あるいは
(b)MHCクラスIIβ鎖の細胞外領域は、β1ドメインおよびβ2ドメインを含む。
項目22
項目13~21のいずれか1項目に記載の方法であって、CIIペプチドは、β1ドメインのN末端に融合している。
項目23
項目13~22のいずれか1項目に記載の方法であって、少なくともα1ドメインはDRA*0101に由来し、少なくともβ1ドメインは、DRB1*0401、DRB1*0404、DRB1*0405、DRB1*0408、DRB1*0409、DRB1*0101、DRB1*0102、DRB1*1001、DRB1*1402、およびDRB1*1303からなる群から選択されるHLA-DR対立遺伝子に由来し、好ましくはDRB1*0401に由来する。
項目24
項目13~23のいずれか1項目に記載の方法であって、CIIペプチドは、AGFKGEQGPKG、好ましくはAGFKGEQGPKGEP、より好ましくはGEPGIAGFKGEQGPKGEPのアミノ酸配列を含む。
項目25
項目13~24のいずれか1項目に記載の方法であって、CIIペプチドは、第1のリジン残基のみを含み、さらなるK(any further K)は変異していて、好ましくはR、A、GまたはQ、より好ましくはRに変異している。
項目26
項目13~25のいずれか1項目に記載の方法であって、
(a)少なくともα1ドメインを含むMHCクラスIIα鎖の細胞外領域、
(b)少なくともβ1ドメインを含むMHCクラスIIβ鎖の細胞外領域、および
(c)リンカーペプチドによってMHCクラスIIα鎖またはMHCクラスIIβ鎖のN末端に融合したコラーゲンIIペプチド(CIIペプチド)は、単一のポリヌクレオチドによってコードされて単一の融合ポリペプチドを発現する。
項目27
項目13~25のいずれか1項目に記載の方法は、
(a)少なくともα1ドメインを含むMHCクラスIIα鎖の細胞外領域をコードする第1のポリヌクレオチド、
(b)少なくともβ1ドメインを含むMHCクラスIIβ鎖の細胞外領域をコードする第2のポリヌクレオチド、および
(c)リンカーペプチドによってMHCクラスIIα鎖またはMHCクラスIIβ鎖のN末端に融合したコラーゲンIIペプチド(CIIペプチド)をコードするポリヌクレオチドを含む。
項目28
項目27に記載の方法であって、MHCクラスIIα鎖は、そのC末端でロイシンジッパーヘテロ二量体化モチーフの第1の機能的ドメインに融合され、かつMHCクラスIIβ鎖は、そのC末端でロイシンジッパーヘテロ二量体化モチーフの第2の相補的機能的ドメインに融合されている。
項目29
項目28に記載の方法であって、第1の機能ドメインおよび第2の相補的機能ドメインは、
(a)酸性および塩基性のロイシンジッパーヘテロ二量体化ドメイン、および/または
(b)jun-fosロイシンジッパーモチーフである。
項目30
項目13~29のいずれか1項目に記載の方法であって、回収された細胞上清および場合によっては回収された細胞はさらに、CIIペプチドを含むMHC II/CIIペプチド複合体を含み、CIIペプチドの第1のリジン残基は未修飾である。
項目31
項目13~30のいずれか1項目に記載の方法によって得られる翻訳後修飾CIIペプチドを含む組換えMHC II/CIIペプチド複合体であって、好ましくは、CIIペプチドの第1のリジン残基は、ヒドロキシリジン(Hyl)であるか、またはO-グリコシル化Hylである。
項目32
項目13~30のいずれか1項目に記載の方法によって得られる翻訳後修飾CIIペプチドを含む組換えMHC II/CIIペプチド複合体を含む組成物であって、好ましくは、CIIペプチドの第1のリジン残基は、ヒドロキシリジン(Hyl)であるか、またはO-グリコシル化Hylである。
項目33
慢性炎症性疾患の治療に使用する項目1~12および32のいずれか1項目に記載の組成物。
項目34
慢性炎症性疾患の治療に使用する項目31に記載の組換えMHC II/CIIペプチド複合体。
項目35
項目33に記載の使用のための組成物または項目34に記載の使用のための組換えMHC II/CIIペプチド複合体であって、慢性炎症性疾患は、関節リウマチ、骨関節炎、乾癬性関節炎、非X線撮影性軸性脊椎関節炎、強直性脊椎炎、若年性特発性関節炎、再発性多軟骨炎、全身性エリテマトーデス、ライム病、メニエール病、自己免疫性内耳疾患(AIED)、またはスティル病である。
項目36
項目1~12および32のいずれか1項目に記載の組成物の組換えMHC II/CIIペプチド複合体、あるいは項目31に記載の翻訳後修飾CIIペプチドを含む組換えMHC II/CIIペプチド複合体を含むMHC II/CIIペプチド複合四量体。
項目37
項目36に記載のMHC II/CIIペプチド複合四量体であって、この四量体は、組換えMHC II/CIIペプチド複合体に結合する多量体化分子、好ましくはストレプトアビジンを含む。
項目38
項目37に記載のMHC II/CIIペプチド複合四量体であって、組換えMHC II/CIIペプチド複合体のそれぞれは、少なくとも1つの共有結合したN末端ビオチンを含む。
項目39
項目37~38に記載のMHC II/CIIペプチド複合四量体であって、多量体化分子は、標識、好ましくは蛍光色素に結合している。
項目40
MHC II/CIIペプチド複合四量体を調製する方法であって、この方法は、
(a)項目1~12および32のいずれか1項目に記載の組成物、または項目31に記載の翻訳後修飾CIIペプチドを含み、かつ少なくとも1つのN末端ビオチン化を含む組換えMHC II/CIIペプチド複合体を提供する工程、
(b)この組成物を、多量体化分子、好ましくはストレプトアビジンと接触させる工程、および
(c)場合によっては、ストレプトアビジンに結合した4個のMHC II/CIIペプチド複合体を含む四量体を単離する工程を含む。
項目41
項目40に記載の方法であって、多量体化分子は、標識、好ましくは蛍光色素に結合している。
項目42
所定の抗原に特異的なT細胞を検出かつ/あるいは定量する生体外での方法であって、この方法は、
(a)項目39に記載のMHC II/CIIペプチド複合四量体を提供する工程、
(b)このMHC II/CIIペプチド複合四量体を、対象の試料、好ましくは前記対象の末梢血細胞を含む試料と接触させる工程、および
(c)T細胞に結合したMHC II/CIIペプチド複合四量体の標識を検出する工程を含む。
項目43
項目42に記載の生体外での方法であって、標識は蛍光色素であり、T細胞に結合したMHC II/CIIペプチド複合四量体は、フローサイトメトリーによって検出される。
項目44
生体外で抗原特異的T細胞を検出するための項目1~12に記載の組成物、または項目36~39に記載のMHC II/CIIペプチド複合四量体の使用。
(合成Galペプチド:GIAGFK(Gal-Hyl)GEQGPKGEP負荷)Aq/galCIIまたはDR4/galCIIと(非修飾ペプチド:GIAGFKGEQGPKGEP;配列番号13負荷)Aq/nCIIまたはDR4/nCII:Aq-mCLIPmtタンパク質を、HEK 293細胞株(Expi293F細胞、Gibcoカタログ番号A14527)またはCHO細胞(図4)中で一過性の遺伝子質導入により発現させ、Hisタグを用いる固定化金属イオンアフィニティークロマトグラフィー(IMAC)とサイズ排除クロマトグラフィー(SEC)の組合せを用いて精製した。次に共有結合したプレペプチドを、トロンビン切断および過剰なGalペプチドまたは非修飾ペプチドの付加によって置換した。最後にSECを実行して、切断されたプレペプチドと過剰なGalペプチドまたは非修飾ペプチドを除去した。Galペプチド:GIAGFK(Gal-Hyl)GEQGPKGEPは、Diogo, D. et al., Curr Opin Rheumatol. 2014; 26: 85-92;Gregersen PK et al., Arthritis Rheum. 1987;30:1205-1213;およびDuke O et al., Clin Exp Immunol. 1982;49:22-30に記述のように、合成・精製し、かつ特性評価した。
動物
関節炎の誘発と臨床評価
治療手順
DTH
T細胞ハイブリドーマ測定
MHC II四量体染色による抗原特異的T細胞の検出
CIIペプチド刺激によるヒトT細胞の活性化
HLA-DRB1*0401陽性の関節リウマチ患者の末梢血からのT細胞の生体外での刺激/分化
結果
実施例1:HEK 293細胞内での機能的に活性なAq/rCIIの生成
実施例2:マウスコラーゲン誘発関節炎モデルでのその場グリコシル化Aq/rCII
実施例3:HEK 293細胞での機能的に活性なDR4/hCIIの生成
実施例4:ヒトでのCIIペプチド特異的T細胞の検出
実施例5:HLA-DRB1*0401陽性関節リウマチ患者の末梢血からのT細胞の生体外での刺激/分化
実施例6:DR4/CIIペプチド複合体中のHisタグ:薬理効果への寄与
実施例7:HEK細胞でのDR4/galCII複合体の組換え生成の妨害
配列表
配列番号1:AGFKGEQGPKG
配列番号2:AGFKGEQGPXG
配列番号3:AGFKGEX2GPKG
配列番号4:AGFKGX3QGPKG
配列番号5:AGFKX4EQGPKG
配列番号6:AGFKGEX2GPX1G
配列番号7:AGFKGX3QGPX1G
配列番号8:AGFKX4EQGPX1G
配列番号9:AGFKGEQGPRG
配列番号10:AGFKGEQGPKGEP
配列番号11:AGFKGEQGPX1GEP
配列番号12:AGFKGEQGPRGEP
配列番号13:GIAGFKGEQGPKGEP
配列番号14:GIAGFKGEQGPX1GEP
配列番号15:GIAGFKGEQGPRGEP
配列番号16:DR4構築物α鎖
配列番号17:hCII259~273ペプチド含有DR4構築物β鎖
配列番号18:最小DR4構築物α鎖
配列番号19:hCII259~273ペプチド含有最小DR4構築物β鎖
配列番号20:hCLIPmut含有DR4構築物β鎖
配列番号21:Aq構築物α鎖
配列番号22:ラットCII259~273ペプチド含有Aq構築物β鎖
配列番号23:Hisタグ不含ラットCII259~273ペプチド含有Aq構築物β鎖
配列番号24:mCLIPペプチド含有Aq構築物β鎖
配列番号25:Hisタグ不含mCLIPペプチド含有Aq構築物β鎖
配列番号26:cFosドメイン
配列番号27:cJuneドメイン
配列番号28:修飾ヒトCLIPペプチド
配列番号29:ラットCIIペプチド259~273
配列番号30:ストレプトアビジンタグ
配列番号31:EKRIWFPYRRF
配列番号32:YKTNFRRYYRF
配列番号33:VLIRHFRKRYY
配列番号34:SAWSHPQFEKGIAGFKGEQGPKGEPSGGGS
Claims (17)
- 組換えMHC II/CIIペプチド複合体を含む組成物であって、
(a)少なくともα1ドメインを含むMHCクラスIIα鎖の細胞外領域、
(b)少なくともβ1ドメインを含むMHCクラスIIβ鎖の細胞外領域、および
(c)リンカーペプチドによってMHCクラスIIα鎖またはMHCクラスIIβ鎖、好ましくはMHCクラスIIβ鎖のN末端に融合されたコラーゲンIIペプチド(CIIペプチド)を含み、
前記CIIペプチドは、AGFKGEQGPKG、AGFKGEQGPXG、AGFKGEXGPKG、AGFKGXQGPKG、AGFKXEQGPKG、AGFKGEXGPXG、AGFKGXQGPXG、およびAGFKXEQGPXGからなる群から選択されるアミノ酸配列を含み、
前記MHC II/CIIペプチド複合体は、翻訳後修飾CIIペプチドを含む、組成物。 - 前記CIIペプチドの第1のリジン残基は、ヒドロキシリジン(Hyl)またはO-グリコシル化Hylである、請求項1に記載の組成物。
- (a)前記第1のリジン残基は、ガラクトシルヒドロキシリジンである、
(b)前記CIIペプチドは、リンカーペプチドによってβ1ドメインのN末端に融合されている、
(c)少なくとも前記α1ドメインはDRA*0101に由来し、少なくとも前記β1ドメインは、DRB1*0401、DRB1*0404、DRB1*0405、DRB1*0408、DRB1*0409、DRB1*0101、DRB1*0102、DRB1*1001、DRB1*1402、およびDRB1*1303からなる群から選択されるHLA-DR対立遺伝子に由来し、好ましくはDRB1*0401に由来する、
(d)前記CIIペプチドは、AGFKGEQGPKG、好ましくはAGFKGEQGPKGEP、より好ましくはGIAGFKGEQGPKGEPのアミノ酸配列を含む、かつ/あるいは
(e)前記CIIペプチドは前記第1のリジン残基のみを含み、さらなるKは変異しており、好ましくはRに変異している、請求項1または2に記載の組成物。 - (a)少なくともα1ドメインを含むMHCクラスIIα鎖の細胞外領域、
(b)少なくともβ1ドメインを含むMHCクラスIIβ鎖の細胞外領域、および
(c)リンカーペプチドによってMHCクラスIIα鎖またはMHCクラスIIβ鎖のN末端に融合したコラーゲンIIペプチド(CIIペプチド)は、単一の融合ポリペプチドとして発現される、請求項1~3のいずれか一項に記載の組成物。 - (a)少なくともα1ドメインを含むMHCクラスIIα鎖の細胞外領域を含む第1のポリペプチド、
(b)少なくともβ1ドメインを含むMHCクラスIIβ鎖の細胞外領域を含む第2のポリペプチド、および
(c)リンカーペプチドによってMHCクラスIIα鎖またはMHCクラスIIβ鎖のN末端に融合したコラーゲンIIペプチド(CIIペプチド)を含む、請求項1~3のいずれか一項に記載の組成物。 - 前記MHCクラスIIα鎖は、そのC末端でロイシンジッパーヘテロ二量体化モチーフの第1の機能的ドメインに融合され、かつ前記MHCクラスIIβ鎖は、そのC末端でロイシンジッパーヘテロ二量体化モチーフの第2の相補的機能的ドメインに融合され、好ましくは、前記第1の機能的ドメインおよび前記第2の相補的機能的ドメインは、
(a)酸性および塩基性のロイシンジッパーヘテロ二量体化ドメイン、および/または
(b)jun-fosロイシンジッパーモチーフである、請求項5に記載の組成物。 - 翻訳後修飾CIIペプチドを含むMHC II/CIIペプチド複合体を生成する方法であって、
(a)哺乳動物細胞を
(i)少なくともα1ドメインを含むMHC IIα鎖の細胞外領域をコードするポリヌクレオチド、
(ii)少なくともβ1ドメインを含むMHC IIβ鎖の細胞外領域をコードするポリヌクレオチド、および
(iii)リンカーペプチドによってMHCクラスIIα鎖またはMHCクラスIIβ鎖、好ましくはMHCクラスIIβ鎖のN末端に融合されたコラーゲンIIペプチド(CIIペプチド)をコードするポリヌクレオチドであって、ここで前記CIIペプチドは、AGFKGEQGPKG、AGFKGEQGPXG、AGFKGEXGPKG、AGFKGXQGPKG、AGFKXEQGPKG、AGFKGEXGPXG、AGFKGXQGPXG、およびAGFKXEQGPXGからなる群から選択されるアミノ酸配列を含む、ポリヌクレオチド
で遺伝子導入する工程、
(b)前記MHC II/CIIペプチド複合体の生成に適する条件で前記哺乳動物細胞を培養する工程、および
(c)翻訳後修飾CIIペプチドを含む前記MHC II/CIIペプチド複合体を含む細胞上清および場合によっては細胞を回収する工程を含み、
場合によっては、さらに前記MHC II/CIIペプチド複合体の前記CIIペプチドの翻訳後修飾を分析する工程を含む、方法。 - 前記CIIペプチドの第1のリジン残基は、ヒドロキシリジン(Hyl)またはO-グリコシル化Hylである、請求項7に記載の方法。
- (a)前記第1のリジン残基は、ガラクトシルヒドロキシリジンである、
(b)少なくとも前記α1ドメインはDRA*0101に由来し、少なくとも前記β1ドメインは、DRB1*0401、DRB1*0404、DRB1*0405、DRB1*0408、DRB1*0409、DRB1*0101、DRB1*0102、DRB1*1001、DRB1*1402、およびDRB1*1303からなる群から選択されるHLA-DR対立遺伝子に由来し、好ましくはDRB1*0401に由来する、
(c)前記CIIペプチドは、AGFKGEQGPKG、好ましくはAGFKGEQGPKGEP、より好ましくはGEPGIAGFKGEQGPKGEPのアミノ酸配列を含む、かつ/あるいは
(d)前記CIIペプチドは前記第1のリジン残基のみを含み、さらなるKは変異しており、好ましくはRに変異している、前記請求項7または8に記載の方法。 - 前記哺乳動物細胞は、
(a)リジンをヒドロキシリジン(Hyl)にヒドロキシル化すること、かつHylをガラクトシルヒドロキシリジン(Gal-Hyl)にガラクトシル化することを含む、コラーゲン中のリジン残基を翻訳後修飾する酵素を含む、かつ/あるいは
(b)リジン水酸化酵素およびコラーゲンガラクトース転移酵素、好ましくはリジン水酸化酵素1(LH1)および/またはリジン水酸化酵素2(LH2)およびコラーゲンガラクトース転移酵素GLT25D1および/またはGLT25D2、好ましくはGLT25D1を含む、請求項7~9のいずれか一項に記載の方法。 - 前記細胞は、
(a)腎細胞、線維芽細胞、または骨芽細胞、好ましくは腎細胞、より好ましくはHEK 293細胞株である、あるいは
(b)リジン水酸化酵素およびコラーゲンガラクトース転移酵素、好ましくはリジン水酸化酵素1(LH1)および/またはリジン水酸化酵素2(LH2)およびコラーゲンガラクトース転移酵素GLT25D1および/またはGLT25D2を組換え発現する遺伝子操作細胞である、請求項10に記載の方法。 - 前記哺乳動物細胞は、
(a)ガラクトシルヒドロキシリシルグルコース転移酵素活性を欠いている、
(b)多機能酵素であるLH3を欠いている、あるいは
(c)ガラクトシルヒドロキシリシルグルコース転移酵素活性を欠く変異性LH3酵素を含む、請求項7~11のいずれか一項に記載の方法。 - (a)少なくともα1ドメインを含むMHCクラスIIα鎖の細胞外領域をコードする第1のポリヌクレオチド、
(b)少なくともβ1ドメインを含むMHCクラスIIβ鎖の細胞外領域をコードする第2のポリヌクレオチド、および
(c)リンカーペプチドによってMHCクラスIIα鎖またはMHCクラスIIβ鎖のN末端に融合したコラーゲンIIペプチド(CIIペプチド)をコードするポリヌクレオチドを含み、
前記MHCクラスIIα鎖は、そのC末端でロイシンジッパーヘテロ二量体化モチーフの第1の機能的ドメインに融合され、かつ前記MHCクラスIIβ鎖は、そのC末端でロイシンジッパーヘテロ二量体化モチーフの第2の相補的機能的ドメインに融合され、好ましくは、
前記第1の機能的ドメインおよび前記第2の相補的機能的ドメインは、
(a)酸性および塩基性のロイシンジッパーヘテロ二量体化ドメイン、および/または
(b)jun-fosロイシンジッパーモチーフである、請求項7~12のいずれか一項に記載の方法。 - 請求項7~13のいずれか一項に記載の方法によって得られる、翻訳後修飾CIIペプチドを含む組換えMHC II/CIIペプチド複合体であって、好ましくは、前記CIIペプチドの第1のリジン残基は、ヒドロキシリジン(Hyl)またはO-グリコシル化Hylである、複合体。
- 慢性炎症性疾患の治療に使用するための、請求項1~6のいずれか一項に記載の組成物、または請求項14に記載の組換えMHC II/CIIペプチド複合体。
- 前記慢性炎症性疾患は、関節リウマチ、骨関節炎、乾癬性関節炎、非X線撮影性軸性脊椎関節炎、強直性脊椎炎、若年性特発性関節炎、再発性多軟骨炎、全身性エリテマトーデス、ライム病、メニエール病、自己免疫性内耳疾患(AIED)、またはスティル病である、請求項15に記載の使用のための組成物または組換えMHC II/CIIペプチド複合体。
- 請求項1~6のいずれか一項に記載の組成物の前記組換えMHC II/CIIペプチド複合体、または請求項14に記載の翻訳後修飾CIIペプチドを含む前記組換えMHC II/CIIペプチド複合体を含むMHC II/CIIペプチド複合四量体。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19191094.2 | 2019-08-09 | ||
EP19191094 | 2019-08-09 | ||
PCT/EP2020/072287 WO2021028350A1 (en) | 2019-08-09 | 2020-08-07 | Production of mhc ii/cii complexes |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2022543960A true JP2022543960A (ja) | 2022-10-17 |
JPWO2021028350A5 JPWO2021028350A5 (ja) | 2023-09-07 |
JP7492538B2 JP7492538B2 (ja) | 2024-05-29 |
Family
ID=67587675
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021572488A Active JP7492538B2 (ja) | 2019-08-09 | 2020-08-07 | Mhc ii/cii複合体の生成 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20220288177A1 (ja) |
EP (1) | EP4010007B1 (ja) |
JP (1) | JP7492538B2 (ja) |
KR (1) | KR20220044687A (ja) |
CN (1) | CN114206945A (ja) |
CA (1) | CA3137810A1 (ja) |
PL (1) | PL4010007T3 (ja) |
WO (1) | WO2021028350A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117897617A (zh) * | 2021-08-30 | 2024-04-16 | 基因泰克公司 | 用于表征mhcii肽结合的测定和试剂 |
WO2023232961A1 (en) | 2022-06-03 | 2023-12-07 | F. Hoffmann-La Roche Ag | Improved production cells |
EP4378533A1 (en) | 2022-11-29 | 2024-06-05 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Patient selection and therapy monitoring for autoimmune disorders |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090227516A1 (en) * | 2005-11-17 | 2009-09-10 | Ahlstrom Corporation | Compound comprising an autoantigenic peptide and a carrier with a mhc binding motif |
US20100168390A1 (en) * | 2007-07-03 | 2010-07-01 | Dako Denmark A/S | Mhc multimers, methods for their generation, labeling and use |
US20130309229A1 (en) * | 2011-01-28 | 2013-11-21 | The United States Government As Represented By The Department Of Veterans Affairs | Recombinant t cell ligands and antibodies that bind b cells for the treatment of autoimmune diseases |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9695410B2 (en) * | 2010-07-15 | 2017-07-04 | Technion Research & Development Foundation Limited | Isolated high affinity entities with T-cell receptor like specificity towards native complexes of MHC class II and glutamic acid decarboxylase (GAD) autoantigenic peptides |
BR112018012344A2 (pt) * | 2015-12-17 | 2018-12-04 | Janssen Biotech Inc | anticorpos que se ligam especificamente a hla-dr e seus usos |
-
2020
- 2020-08-07 EP EP20750299.8A patent/EP4010007B1/en active Active
- 2020-08-07 US US17/633,916 patent/US20220288177A1/en active Pending
- 2020-08-07 KR KR1020217043364A patent/KR20220044687A/ko unknown
- 2020-08-07 CA CA3137810A patent/CA3137810A1/en active Pending
- 2020-08-07 CN CN202080056542.4A patent/CN114206945A/zh active Pending
- 2020-08-07 WO PCT/EP2020/072287 patent/WO2021028350A1/en unknown
- 2020-08-07 JP JP2021572488A patent/JP7492538B2/ja active Active
- 2020-08-07 PL PL20750299.8T patent/PL4010007T3/pl unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090227516A1 (en) * | 2005-11-17 | 2009-09-10 | Ahlstrom Corporation | Compound comprising an autoantigenic peptide and a carrier with a mhc binding motif |
US20100168390A1 (en) * | 2007-07-03 | 2010-07-01 | Dako Denmark A/S | Mhc multimers, methods for their generation, labeling and use |
US20130309229A1 (en) * | 2011-01-28 | 2013-11-21 | The United States Government As Represented By The Department Of Veterans Affairs | Recombinant t cell ligands and antibodies that bind b cells for the treatment of autoimmune diseases |
Non-Patent Citations (1)
Title |
---|
THE JOURNAL OF IMMUNOLOGY, vol. 176, no. 3, JPN6023021936, 2006, pages 1525 - 1533, ISSN: 0005071529 * |
Also Published As
Publication number | Publication date |
---|---|
KR20220044687A (ko) | 2022-04-11 |
WO2021028350A1 (en) | 2021-02-18 |
CA3137810A1 (en) | 2021-02-18 |
CN114206945A (zh) | 2022-03-18 |
EP4010007B1 (en) | 2023-11-15 |
US20220288177A1 (en) | 2022-09-15 |
EP4010007C0 (en) | 2023-11-15 |
JP7492538B2 (ja) | 2024-05-29 |
PL4010007T3 (pl) | 2024-04-08 |
EP4010007A1 (en) | 2022-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11760787B2 (en) | B7-H5, a costimulatory polypeptide | |
JP7492538B2 (ja) | Mhc ii/cii複合体の生成 | |
KR102557834B1 (ko) | 신규의 세포 태그의 발현 | |
EP1973573B1 (en) | Methods and compositions for expanding t regulatory cells | |
EA024877B1 (ru) | Связывающие множество мишеней белки, обладающие антагонистическими свойствами по отношению к cd86 | |
EP2776460B1 (en) | Fusion protein comprising an interleukin 4 and interleukin 10 | |
WO2012001647A2 (en) | Polypeptides and uses thereof as a drug for treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders | |
JPH09508009A (ja) | Fas抗原を結合するリガンド | |
JP2022528030A (ja) | 多機能性融合タンパク質及びその使用 | |
JP7406620B2 (ja) | 関節炎治療のためのhla-dr/ciiペプチド複合体 | |
CA2516834C (en) | Polypeptides and methods for making the same | |
JP2022525921A (ja) | 免疫エフェクタ細胞の特異的活性化のためのインターロイキン2受容体(il2r)およびインターロイキン2(il2)バリアント | |
US20230348560A1 (en) | Chimeric ilt receptor compositions and methods | |
JP2024515707A (ja) | TGF-βを持つ抗原提示ポリペプチド複合体及びその使用方法 | |
KR20210150993A (ko) | Pa63 도메인 4 변이체를 세포외 결합 도메인으로 포함하는 키메라 항원 수용체 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220610 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230530 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20230830 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231128 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240228 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240507 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240517 |